{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-028092","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2026-07-09T18:55:22+00:00","discovered_at":"2026-07-09T18:56:00.491226+00:00","generated_at":"2026-07-09T18:56:04.870561+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ionis eplontersen Phase 3 ATTR-CM trial misses primary endpoint; monotherapy subgroup shows nominal benefit","bullets":["CARDIO-TTRansform trial did not meet primary composite endpoint of CV mortality and recurrent CV events vs placebo at Week 140.","In prespecified subgroup, eplontersen monotherapy showed nominally significant HR of 0.71 on the composite outcome.","57% of patients on stabilizer at baseline; no treatment effect observed in that subgroup.","Secondary, imaging, and biomarker analyses favored eplontersen; safety profile consistent with prior results.","Full results to be presented at ESC Congress in August 2026; Ionis and AstraZeneca continue analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-028092","json":"https://secwatch.observer/filing/0001140361-26-028092.json","markdown":"https://secwatch.observer/filing/0001140361-26-028092.md","text":"https://secwatch.observer/filing/0001140361-26-028092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036126028092/0001140361-26-028092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036126028092/ef20077664_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-09T18:56:04.870561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}